CINCINNATI--(BUSINESS WIRE)--Mar. 15, 2018--
Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company
focused on advancing first-in-class treatments for ocular diseases,
today announced that President and Founder, Joseph Gardner, Ph.D., will
present at the Oppenheimer 28th Annual Healthcare Conference
on Tuesday, March 20, 2018 at 8:00 a.m. Eastern Time in New York, N.Y.
Dr. Gardner will provide a corporate overview and business update.
The presentation will be webcast live and may be accessed by visiting
Aerpio's website at http://ir.aerpio.com/.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on
advancing first-in-class treatments for ocular diseases. The Company’s
lead compound, AKB‐9778, is a small molecule activator of the Tie2
pathway and is in clinical development for the treatment of
non-proliferative diabetic retinopathy. For more information please
View source version on businesswire.com: http://www.businesswire.com/news/home/20180315005395/en/
Source: Aerpio Pharmaceuticals, Inc.
Investor & Media:
Michael Rogers, 513-985-1958
Burns McClellan, on behalf of Aerpio